Table 1.
Comparisons between Cervarix and Gardasil
| Category | Cervarix | Gardasil |
|---|---|---|
| HPV types Included | HPV 16 and 18 | HPV 16, 18, 6, 11 |
| Production system | Insect cells infected with recombinant baculovirus | Yeast |
| Adjuvant | ASO4 (aluminium salt + MPL (3-O-desacyl-4'-monophosphoryl lipid A)) | Alum |
| Diseases covered | Anogenital cancers, including cervical, vulval, vaginal, and anal cancers and their associated precursor lesions (and a subset of head and neck cancers) | Anogenital cancers, including cervical, vulval, vaginal, and anal cancers and their associated precursor lesions (and a subset of head and neck cancers) Genital warts and laryngeal papillomas |
| Available data regarding Length of protection | 5.5 years | At least 5 years |
| Dose | 0.5 mL dose containing 20 μg HPV 16 L1 and 20 μg HPV18 L1 |
0.5 mL dose containing 20 μg HPV6 L1, 40 μg HPV 11 L1, 40 μg HPV16 L1 and 20 μg HPV18 L1 |
| Recommended administration Route and regimen | Three intramuscular injections at 0, 1, and 6 months | Three intramuscular injections at 0, 2, and 6 months |
| Recommended age group for vaccination | 10–25 | 9–26 |
| Price (US$) | Approx. $100 per dose | Approx. $120 per dose |